Engineered Vesicles Fight Antimicrobial Resistance

Researchers at Pusan National University have made significant strides in the battle against antimicrobial resistance through the development of engineered extracellular vesicles (EVs). These vesicles, derived from Lacticaseibacillus paracasei, are tailored to target harmful bacteria, specifically Staphylococcus aureus, using a novel endolysin displayed on their surface.

Background on Antimicrobial Resistance

Antimicrobial resistance (AMR) poses a grave challenge to global health. The rapid evolution of pathogenic bacteria, such as Escherichia coli and Staphylococcus aureus, has led to infections that are increasingly difficult to treat with conventional antibiotics. According to the World Health Organization, AMR is responsible for approximately 700,000 deaths annually. This growing concern necessitates the exploration of alternative therapeutic strategies.

The Role of Endolysins

Endolysins are enzymes with the ability to degrade the cell walls of bacteria, offering a targeted approach to tackling pathogenic strains. These proteins are typically derived from bacteriophages or engineered microbes. While endolysins show great potential for being effective against bacterial infections, their usage has been limited by various factors, including:

• High production costs: Current methods for producing endolysins are often economically unsustainable.
• Instability: Endolysins can lose their efficacy during storage and circulation.
• Degradation: They are susceptible to enzymatic degradation, leading to loss of function.

Development of EVs from Lacticaseibacillus paracasei

To overcome these limitations, the team from Pusan National University focused on utilizing EVs—membrane-bound nanoparticles known for their ability to transport biologically active molecules. In their study, the researchers executed the following steps:

1. Culture Preparation: They cultured Lacticaseibacillus paracasei in a controlled laboratory environment.
2. EV Isolation: Collected the EVs through high-speed centrifugation techniques.
3. Proteomic Analysis: Conducted comprehensive analysis, identifying 13 surface-displaying proteins (SDPs) linked to the isolated EVs.

Significant Findings

Among these discoveries, the protein LP-SDP3 stood out as a promising candidate. As Professor Kwang-sun Kim noted, “This is the first time SDPs from the EVs of LAB species have been characterized.” The identification of LP-SDP3, in conjunction with its homologous proteins in E. coli and various LAB strains, demonstrated a conserved function across these species.

Application of Engineered EVs

Subsequently, the team incorporated the endolysin PlyF307SQ-8C into the engineered EVs that displayed LP-SDP3. The engineered EVs exhibited remarkable selectivity for S. aureus, effectively targeting and eliminating these harmful bacteria without inducing antimicrobial resistance. Notably, these EVs maintained stability across varying temperature and pH conditions.

With a potential for large-scale production, these engineered EVs present a cost-effective antibacterial therapy solution that could reshape treatment modalities in the coming years. Professor Kim emphasizes, “In 5 to 10 years, this research could help shift away from antibiotics towards safe, smart, and sustainable bioengineered alternatives.”

Conclusion

The identification of the novel LP-SDP3 protein alongside the innovative engineering of EVs demonstrate a significant advancement in combating AMR. As the scientific community continues to explore and refine these techniques, the future of antibacterial therapies looks promising.

References

Lee, J., et al. (2025). Surface-displaying protein from Lacticaseibacillus paracasei–derived extracellular vesicles: Identification and utilization in the fabrication of an endolysin-displaying platform against Staphylococcus aureus. Chemical Engineering Journal. Retrieved from Science X.